Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.
Google Scholar
Kotadia ID, Williams SE, O’Neill M. Supraventricular tachycardia: an overview of diagnosis and management. Clin Med (Lond). 2020;20(1):43–7.
Google Scholar
Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, Charron P, Corrado D, Dagres N, de Chillou C, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC) endorsed by the association for European paediatric and congenital cardiology (AEPC). Eur Heart J. 2022;43(40):3997–4126.
Google Scholar
Sirichand S, Killu AM, Padmanabhan D, Hodge DO, Chamberlain AM, Brady PA, Kapa S, Noseworthy PA, Packer DL, Munger TM et al. Incidence of idiopathic ventricular arrhythmias: A Population-Based study. Circ Arrhythm Electrophysiol 2017;10(2).
Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, Ardissino D, Califf RM, Granger CB, Ohman EM, et al. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction*. Crit Care Med. 2011;39(1):78–83.
Google Scholar
Soar J, Böttiger BW, Carli P, Couper K, Deakin CD, Djärv T, Lott C, Olasveengen T, Paal P, Pellis T, et al. European resuscitation Council guidelines 2021: adult advanced life support. Resuscitation. 2021;161:115–51.
Google Scholar
Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, et al.: 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS): developed by the task force for the management of atrial fibrillation of the European society of cardiology (ESC), with the special contribution of the European heart rhythm association (EHRA) of the ESC. Endorsed by the European stroke organisation (ESO). Eur Heart J. 2024;45(36):3314–414.
Google Scholar
Bedford JP, Johnson A, Redfern O, Gerry S, Doidge J, Harrison D, Rajappan K, Rowan K, Young JD, Mouncey P, et al. Comparative effectiveness of common treatments for new-onset atrial fibrillation within the ICU: accounting for physiological status. J Crit Care. 2022;67:149–56.
Google Scholar
Walkey AJ, Evans SR, Winter MR, Benjamin EJ. Practice patterns and outcomes of treatments for atrial fibrillation during sepsis: A Propensity-Matched cohort study. Chest. 2016;149(1):74–83.
Google Scholar
Balik M, Kolnikova I, Maly M, Waldauf P, Tavazzi G, Kristof J. Propafenone for supraventricular arrhythmias in septic shock—Comparison to Amiodarone and Metoprolol. J Crit Care. 2017;41:16–23.
Google Scholar
Fatima N, Mandava K, Khatoon F, Badar J, Begum SF, Narasimhan C, Daljeet K, Mohammed W. CLInical profile and side effects of chronic use of oral Amiodarone in cardiology outpatients department (CLIPSE-A Study)- A prospective observational study. Annals Med Surg. 2022;80:104167.
Google Scholar
Drikite L, Bedford JP, O’Bryan L, Petrinic T, Rajappan K, Doidge J, Harrison DA, Rowan KM, Mouncey PR, Young D, et al. Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review. Crit Care. 2021;25(1):257.
Google Scholar
Medić F, Bakula M, Alfirević M, Bakula M, Mucić K, Marić N. AMIODARONE AND THYROID DYSFUNCTION. Acta Clin Croat. 2022;61(2):327–41.
Google Scholar
Ruzieh M, Moroi MK, Aboujamous NM, Ghahramani M, Naccarelli GV, Mandrola J, Foy AJ. Meta-Analysis comparing the relative risk of adverse events for Amiodarone versus placebo. Am J Cardiol. 2019;124(12):1889–93.
Google Scholar
Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomström-Lundqvist C, Calkins H, Corrado D, Deftereos SG, Diller G-P, et al. 2019 ESC guidelines for the management of patients with supraventricular tachycardiathe task force for the management of patients with supraventricular tachycardia of the European society of cardiology (ESC): developed in collaboration with the association for European paediatric and congenital cardiology (AEPC). Eur Heart J. 2019;41(5):655–720.
Google Scholar
Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta Cardiol. 2010;65(5):565–70.
Google Scholar
Wong GWK, Boyda HN, Wright JM. Blood pressure Lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane Database Syst Reviews 2016;(3).
Gorczynski RJ, Shaffer JE, Lee RJ. Pharmacology of ASL-8052, a novel β-Adrenergic receptor antagonist with an ultrashort duration of action. J Cardiovasc Pharmacol. 1983;5(4):668–77.
Google Scholar
Wiest D. Esmolol. A review of its therapeutic efficacy and Pharmacokinetic characteristics. Clin Pharmacokinet. 1995;28(3):190–202.
Google Scholar
Iguchi S, Iwamura H, Nishizaki M, Hayashi A, Senokuchi K, Kobayashi K, Sakaki K, Hachiya K, Ichioka Y, Kawamura M. Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101. Chem Pharm Bull (Tokyo). 1992;40(6):1462–9.
Google Scholar
Atarashi H, Kuruma A, Yashima M, Saitoh H, Ino T, Endoh Y, Hayakawa H. Pharmacokinetics of Landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther. 2000;68(2):143–50.
Google Scholar
Krumpl G, Ulc I, Trebs M, Kadlecová P, Hodisch J. Pharmacokinetics and pharmacodynamics of two different Landiolol formulations in a healthy Caucasian group. Eur J Pharm Sci. 2016;92:64–73.
Google Scholar
Iwahashi N, Takahashi H, Abe T, Okada K, Akiyama E, Matsuzawa Y, Konishi M, Maejima N, Hibi K, Kosuge M, et al. Urgent control of rapid atrial fibrillation by Landiolol in patients with acute decompensated heart failure with severely reduced ejection fraction. Circ Rep. 2019;1(10):422–30.
Google Scholar
Schnaubelt S, Eibensteiner F, Oppenauer J, Tihanyi D, Neymayer M, Brock R, Kornfehl A, Veigl C, Al Jalali V, Anders S et al. Hemodynamic and rhythmologic effects of Push-Dose Landiolol in critical Care-A retrospective Cross-Sectional study. Pharmaceuticals (Basel) 2023;16(2).
Johnston BW, Chean CS, Duarte R, Hill R, Blackwood B, McAuley DF, Welters ID. Management of new onset atrial fibrillation in critically unwell adult patients: a systematic review and narrative synthesis. Br J Anaesth. 2022;128(5):759–71.
Google Scholar
Van Gelder IC, Hemels MEW. The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm. EP Europace. 2006;8(11):943–9.
Google Scholar
Gupta D, Rienstra M, van Gelder IC, Fauchier L. Atrial fibrillation: better symptom control with rate and rhythm management. Lancet Reg Health – Europe. 2024;37:100801.
Google Scholar
Levy B, Slama M, Lakbar I, Maizel J, Kato H, Leone M, Okada M. Landiolol for treatment of New-Onset atrial fibrillation in critical care: A systematic review. J Clin Med. 2024;13(10):2951.
Google Scholar
Krumpl G, Ulc I, Trebs M, Kadlecová P, Hodisch J. Bolus application of Landiolol and esmolol: comparison of the Pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group. Eur J Clin Pharmacol. 2017;73(4):417–28.
Google Scholar
Bucci T, Proietti R, Lip GYH. Risk of death and thromboembolic events in patients with supraventricular arrhythmias admitted to the emergency department. EP Europace 2024;. Volume 26, Issue Supplement_1, May 2024, euae102.833
Fornage LB, Christine ON, DS R, WE R, LR S, Brown LH. Prehospital intervention improves outcomes for patients presenting in atrial fibrillation with rapid ventricular response. Prehospital Emerg Care. 2024;28(7):910–9.
Google Scholar
Nasoufidou A, Papazoglou AS, Stachteas P, Karagiannidis E, Samaras A, Alexiou S, Mourtzos MA, Kassimis G, Fragakis N. Intravenous Landiolol for rate control in supraventricular tachyarrhythmias in patients with left ventricular dysfunction: A systematic review and Meta-Analysis. J Clin Med 2024, 13(6).
Heliste M, Pettilä V, Berger D, Jakob SM, Wilkman E. Beta-blocker treatment in the critically ill: a systematic review and meta-analysis. Ann Med. 2022;54(1):1994–2010.
Google Scholar
Whitehouse T, Hossain A, Perkins GD, Gordon AC, Bion J, Young D, McAuley D, Singer M, Lord J, Gates S et al. Landiolol and Organ Failure in Patients With Septic Shock: The STRESS-L Randomized Clinical Trial. JAMA 2023.
Rehberg S, Frank S, Černý V, Cihlář R, Borgstedt R, Biancofiore G, Guarracino F, Schober A, Trimmel H, Pernerstorfer T, et al. Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP). Intensive Care Med. 2024;50(10):1622–34.
Google Scholar
Schnaubelt S, Eibensteiner F, Sulzgruber P. Landiolol in septic Shock — No One-Size-Fits-All approach. Heart Lung Circulation. 2024;33(4):e31–2.
Google Scholar
Hariri G, Urbina T, Mazerand S, Bige N, Baudel JL, Ait-Oufella H. Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients. Crit Care. 2021;25(1):33.
Google Scholar
Ditali V, Garatti L, Morici N, Villanova L, Colombo C, Oliva F, Sacco A. Effect of Landiolol in patients with tachyarrhythmias and acute decompensated heart failure (ADHF): a case series. ESC Heart Fail. 2022;9(1):766–70.
Google Scholar
Novotny J, Klein MM, Haum M, Fichtner SR, Thienel MB. Prevalence of pathological arrhythmia in patients triaged to cardiac arrhythmia in the emergency department: a preliminary study. Int J Emerg Med. 2022;15(1):49.
Google Scholar
Smith G, McD Taylor D, Morgans A, Cameron P. Prehospital management of supraventricular tachycardia in victoria, australia: epidemiology and effectiveness of therapies. Emerg Med Australasia. 2014;26(4):350–5.
Google Scholar
Fornage LB, O’Neil C, Dowker SR, Wanta ER, Lewis RS, Brown LH. Prehospital intervention improves outcomes for patients presenting in atrial fibrillation with rapid ventricular response. Prehospital Emerg Care. 2024;28(7):910–9.
Google Scholar
Berkenbush M, Sherman N, Jain N, Cosmi P. Prehospital treatment of atrial fibrillation: infusion pump for bolus and infusion? Prehospital Emerg Care:1–4.2025;29(1):85-88. https://doi.org/10.1080/10903127.2024.2349745. Epub 2024 May 21.
Ball J, Mahony E, Nehme E, Voskoboinik A, Hogarty J, Dawson LP, Horrigan M, Kaye DM, Stub D, Nehme Z. The burden of atrial fibrillation on emergency medical services: A population-based cohort study. Int J Cardiol. 2024;414:132397.
Google Scholar
Vásquez-Tirado GA, Quispe-Castañeda CV, Meregildo-Rodríguez ED, Cuadra-Campos M, Segura-Plasencia NM, Arbayza-Avalos YK, Alva-Guarniz HN, Guzmán-Aguilar WM, Zavaleta-Alaya P. Association of beta blockers and mortality in adults with septic shock: systematic review and meta-analysis of randomized clinical trial. Front Med 2024;Sep 24:11:1448573; eCollection 2024.